NPS Pharmaceuticals Company Profile (NASDAQ:NPSP)

About NPS Pharmaceuticals (NASDAQ:NPSP)

NPS Pharmaceuticals logoNPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NPSP
  • CUSIP: 62936P10
  • Web:
Average Prices:
  • 50 Day Moving Avg: $46.00
  • 200 Day Moving Avg: $34.00
  • 52 Week Range: $22.00 - $46.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 23.00
  • P/E Growth: 0
  • Net Margins: -2.96%
  • Return on Equity: -5.98%
  • Return on Assets: -2.77%
  • Average Volume: 4.38 million shs.

Frequently Asked Questions for NPS Pharmaceuticals (NASDAQ:NPSP)

What is NPS Pharmaceuticals' stock symbol?

NPS Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."

How were NPS Pharmaceuticals' earnings last quarter?

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) released its earnings results on Wednesday, February, 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.06 by $0.08. The firm earned $66.70 million during the quarter, compared to analysts' expectations of $69.30 million. NPS Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 5.98%. View NPS Pharmaceuticals' Earnings History.

Who are some of NPS Pharmaceuticals' key competitors?

How do I buy NPS Pharmaceuticals stock?

Shares of NPS Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NPS Pharmaceuticals' stock price today?

One share of NPS Pharmaceuticals stock can currently be purchased for approximately $46.00.

MarketBeat Community Rating for NPS Pharmaceuticals (NASDAQ NPSP)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about NPS Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NPS Pharmaceuticals (NASDAQ:NPSP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for NPS Pharmaceuticals (NASDAQ:NPSP)
No equities research coverage for this company has been tracked by


Earnings History for NPS Pharmaceuticals (NASDAQ:NPSP)
Earnings by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)
Earnings History by Quarter for NPS Pharmaceuticals (NASDAQ NPSP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/18/2015Q414$0.06($0.02)$69.30 million$66.70 millionViewN/AView Earnings Details
11/10/2014Q314$0.01($0.02)$59.50 million$57.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.01)$0.02$53.06 million$56.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.06)$48.30 million$44.04 millionViewListenView Earnings Details
2/18/2014Q413$0.02$0.07$44.22 million$54.45 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)($0.13)$31.62 million$36.50 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.13)($0.09)$27.56 million$25.43 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.09)($0.14)$28.93 million$27.10 millionViewListenView Earnings Details
11/9/2012Q312($0.16)($0.04)$28.18 million$27.02 millionViewN/AView Earnings Details
8/1/2012($0.09)$0.08ViewN/AView Earnings Details
5/3/2012($0.11)($0.12)ViewN/AView Earnings Details
2/15/2012($0.11)($0.10)ViewN/AView Earnings Details
11/3/2011($0.10)($0.14)ViewN/AView Earnings Details
8/2/2011($0.07)($0.07)ViewN/AView Earnings Details
5/3/2011($0.12)($0.13)ViewN/AView Earnings Details
2/15/2011($0.20)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NPS Pharmaceuticals (NASDAQ:NPSP)
Current Year EPS Consensus Estimate: $1 EPS
Next Year EPS Consensus Estimate: $2 EPS


Dividend History for NPS Pharmaceuticals (NASDAQ:NPSP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NPS Pharmaceuticals (NASDAQ:NPSP)
Insider Trades by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)
Insider Trades by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/10/2015Susan E GrafVPSell6,711$45.87$307,833.57View SEC Filing  
12/17/2014Joseph J RogusSVPSell16,467$35.00$576,345.00View SEC Filing  
12/17/2014Luke M BesharCFOSell52,258$35.00$1,829,030.00View SEC Filing  
12/17/2014Rachel R SeliskerDirectorSell3,708$34.59$128,259.72View SEC Filing  
12/8/2014Rachel R SeliskerDirectorSell23,157$34.50$798,916.50View SEC Filing  
11/28/2014Rachel R SeliskerDirectorSell11,635$34.50$401,407.50View SEC Filing  
11/17/2014Joseph J RogusSVPSell26,782$30.00$803,460.00View SEC Filing  
11/11/2014Rachel R SeliskerDirectorSell15,188$29.50$448,046.00View SEC Filing  
10/31/2014Luke M BesharCFOSell10,000$29.00$290,000.00View SEC Filing  
10/27/2014Luke M BesharCFOSell30,635$26.75$819,486.25View SEC Filing  
2/13/2014Georges GemayelDirectorSell6,188$37.70$233,287.60View SEC Filing  
1/8/2014Luke BesharCFOSell31,588$35.01$1,105,895.88View SEC Filing  
12/26/2013Luke BesharCFOSell37,874$30.02$1,136,977.48View SEC Filing  
12/23/2013James GroningerDirectorSell3,000$29.50$88,500.00View SEC Filing  
12/18/2013Ed StratemeierSVPSell205,432$25.13$5,162,506.16View SEC Filing  
9/20/2013Luke BesharCFOSell50,000$30.26$1,513,000.00View SEC Filing  
9/16/2013Joseph RogusVPSell25,312$28.11$711,520.32View SEC Filing  
9/16/2013Luke BesharCFOSell50,000$27.89$1,394,500.00View SEC Filing  
8/30/2013Roger GarceauCMOSell110,000$25.18$2,769,800.00View SEC Filing  
8/20/2013James GroningerDirectorSell16,900$23.21$392,249.00View SEC Filing  
5/9/2013Luke M BesharCFOSell45,150$14.18$640,227.00View SEC Filing  
11/15/2012Glenn R MelroseSVPBuy11,000$9.09$99,990.00View SEC Filing  
10/3/2012Roger GarceauCMOSell140,625$9.51$1,337,343.75View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NPS Pharmaceuticals (NASDAQ:NPSP)
Latest Headlines for NPS Pharmaceuticals (NASDAQ:NPSP)
DateHeadline logoDicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical Officer - June 8 at 9:48 AM logoSyndax Pharmaceuticals (SNDX) Names Pierre Legault to Board of Directors - January 6 at 2:13 AM logoSyndax Adds Global Pharmaceutical Business Veteran to Board of Directors - January 5 at 9:02 PM logoShire (SHPG) Gets EU Nod for Label Expansion of Revestive - July 8 at 6:34 PM logoA Deep Dive Into Shire's Business - Seeking Alpha - May 30 at 4:40 PM logoCompany Overview of NPS Pharmaceuticals, Inc. - April 11 at 10:07 PM logoSmart-Money Healthcare Investing Focuses On Major Biotech Stocks - Seeking Alpha - March 28 at 4:33 PM logoNPS Pharmaceuticals, Inc. Company Profile - February 25 at 4:46 PM logoShire Fourth-Quarter Earnings Exceed Analysts' Expectation - February 11 at 9:02 AM logoShire target NPS Pharma wins FDA approval for Natpara - January 26 at 3:43 AM logoShire shares jump as drug approval vindicates $5.2 bln NPS purchase - January 26 at 3:16 AM logoU.S. FDA approves NPS drug, in move validating Shire takeover deal - January 23 at 7:39 PM logoFDA approves NPS drug, in move validating Shire takeover deal - January 23 at 7:00 PM logo[video]Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses - January 12 at 8:32 PM logoU.S. equities end lower... - January 12 at 4:45 PM logoShire acquires US rival NPS Pharmaceuticals for $5.2bn - January 12 at 8:18 AM logoNPS a "natural fit" for pharma group Shire, says UBS - January 12 at 6:21 AM logoCramer: Hold Your Fire - January 12 at 5:17 AM logoShire to buy NPS for $5.2 billion to boost rare disease drugs - January 11 at 3:27 PM logoShire to buy NPS for $5.2 bln to boost rare disease drugs - January 11 at 3:25 PM logoShire to buy specialty drugmaker NPS Pharma for $5.2 billion - January 11 at 1:27 PM logoShire considering bid for NPS Pharmaceuticals - Bloomberg - December 17 at 12:06 PM logoNPS reports 3Q loss - November 10 at 4:39 PM



NPS Pharmaceuticals (NPSP) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff